Vera Therapeutics Inc’s recent filing unveils that its PRESIDENT AND CEO Fordyce Marshall unloaded Company’s shares for reported $0.3 million on Feb 21 ’25. In the deal valued at $27.89 per share,10,613 shares were sold. As a result of this transaction, Fordyce Marshall now holds 213,740 shares worth roughly $4.83 million.
Then, Fordyce Marshall sold 9,075 shares, generating $250,882 in total proceeds. Upon selling the shares at $27.65, the PRESIDENT AND CEO now owns 204,665 shares.
Before that, MARSHALL FORDYCE bought 9,075 shares. Vera Therapeutics Inc shares valued at $245,932 were divested by the Director at a price of $27.10 per share.
A number of analysts have revised their coverage, including Wolfe Research’s analysts, who began to cover the stock in early February with a ‘”an Outperform”‘ rating. Goldman began covering VERA with “Buy” recommendation on January 28, 2025. Wells Fargo started covering the stock on November 21, 2024. It rated VERA as “an Overweight”.
Price Performance Review of VERA
On Tuesday, Vera Therapeutics Inc [NASDAQ:VERA] saw its stock jump 1.94% to $22.62. Over the last five days, the stock has lost -26.82%. Vera Therapeutics Inc shares have fallen nearly -46.51% since the year began. Nevertheless, the stocks have fallen -40.50% over the past one year.
How much short interest is there in Vera Therapeutics Inc?
A steep rise in short interest was recorded in Vera Therapeutics Inc stocks on 2025-05-30, growing by 2.99 million shares to a total of 8.95 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-30 was 5.96 million shares. There was a rise of 33.41%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 16, 2024 when Scotiabank began covering the stock and recommended ‘”a Sector outperform”‘ rating.
